FINEARTS-HF trial results in clinically meaningful reduction in the composite endpoint of CV death
The study could be of high clinical value to cardiologists who are seeking an optimal treatment of choice for HF patients, which…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Research
Dual-action therapy shows promise against aggressive oral cancer
A new treatment combining tiny iron particles and nitric oxide gas shows promise in targeting oral cancer cells for destruction
Eisai and Biogen’s Leqembi launch in China marks turning point in Alzheimer’s treatment, says…
Leqembi is the only approved treatment in China that has shown efficacy in slowing the progression of Alzheimer’s by directly…
NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical…
According to GlobalData, NewAmsterdam’s obicetrapib is expected to be the most promising agent to launch in the dyslipidemia…
Pfizer’s gene therapy for Haemophilia A receives positive topline results from Phase 3 Study
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
RCC diagnosed incident cases to reach 230,000 in 8MM by 2033: GlobalData
According to GlobalData epidemiologists, there were 19.90 per cent of stage III diagnosed incident cases of RCC and 17.90 per cent…
Recent study shows BioCity’s potential to differentiate in kidney disease space
The study could be of high clinical value to nephrologists who are seeking an optimal treatment of choice for IgAN patients, which…
SynaptixBio collaborates with Evotec to boost search for rare disease therapies
SynaptixBio and Evotec are working to develop new candidate therapies for a specific leukodystrophy
Synergistic safety profile could increase sublingual apomorphine competitiveness: GlobalData
New findings from EAN 2024 highlight potential competitive edge for Kynmobi in managing levodopa Wear-Off
Penn pioneers a ‘one-pot platform’ to promptly produce mRNA delivery particles
New lipid platform enables rapid synthesis of molecules that can shuttle therapeutics for a range of diseases with a high degree…
Healey platform data to pave phase III path for Prilenia’s pridopidine: GlobalData
Prilenia Therapeutics presented promising results from the additional analyses of the Phase II Healey ALS Platform Trial…
VNS and cenobamate combo therapy success paves way for cenobamate monotherapy, says GlobalData
The combination therapy demonstrated significant improvements in seizure control, highlighting its potential as a safe and…
Structure, functions and methods to remove endotoxins from biologic formulations
This review summarizes the following parameters of endotoxins: structure, mechanism of action, sources, testing methods, unit…
Preventative treatment of chronic migraine will continue to evolve in short-term with anti-CGRP mAbs…
The positive results from the study indicate that the treatment for chronic disease prevention will continue to evolve in the…
Neurolief announces results from clinical trial of brain neuromodulation system
Neurolief previously received Breakthrough Device designation from the FDA for its technology targeting Major Depression
Merck discontinues Phase III TrilynX Study in locally advanced head and neck cancer
The decision follows a pre-planned interim analysis which found that the trial would be unlikely to meet its primary objective of…
Emmes, ILiAD partner to conduct Phase III clinical trials of Pertussis vaccine
Veridix AI, part of Emmes Group, to provide Advantage eClinical and other platform capabilities critical to accelerate and improve…
Takeda’s phase 2b study of Mezagitamab shows potential to transform treatment of primary immune…
Takeda Plans to Initiate Global Phase 3 Trial of Mezagitamab in ITP in the Second Half of FY2024
Sun Pharma’s Utreglutide shows weight loss, gluco-metabolic and lipid-lowering efficacy
GL0034 (Utreglutide) administered once weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters…
CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs.…
A BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting